It is natively an orally-active compound
That is why in-person is the recommended default here, with telehealth assessments available on request
In published Phase 3 trials, the mean weight loss reported for retatrutide at 80 weeks (28.3%) exceeded the mean reported for tirzepatide in SURMOUNT-1 at 72 weeks (22.5%) [1][2][9]
Visit our List of Drugs Search Tool support page for step-by-step instructions on searching by drug name, class, or alphabetically, and to learn how to interpret your search results, including coverage tiers, restrictions, dosage information, and formulary alternatives
We also sorted through additional products featuring the ingredient to find shopper-loved options that have a greater than 4.5-star rating from hundreds of reviews
Researchers use the CJC-1295 No DAC + Ipamorelin 10mg blend for growth hormone pathway investigation and hormonal system modeling